Victor Huber, PhD
My lab focuses on host immune responses against pathogens, in particular influenza viruses. This interest includes evaluation of vaccine-induced immune responses that mediate optimal protection against primary influenza virus infection. In addition, our lab studies the contribution of host responses against influenza viruses that predispose to deadly secondary bacterial infections, like pneumonia. The overall goal of our research is to develop both vaccines and therapies that will improve our ability to limit both disease severity and death.
Areas of expertise:
Immunology, influenza virology, vaccinology
McCormick K, Jiang Z, Zhu L, Lawson SR, Langenhorst R, Ransburgh R, Brunick C, Tracy MC, Hurtig HR, Mabee LM, Mingo M, Li Y, Webby RJ, Huber VC, and Fang Y. Construction and immunogenicity evaluation of recombinant influenza A viruses containing chimeric hemagglutinin genes derived from genetically divergent influenza A H1N1 subtype viruses. PLoS ONE. 10:e0127649, 2015.
Klonoski JM, Hurtig HR, Juber BA, Schuneman MJ, Bickett TE, Svendsen JM, Burum B, Penfound TA, Sereda G, Dale JB, Chaussee MS, and Huber VC. Vaccination against the M protein of Streptococcus pyogenes prevents death after influenza virus:S. pyogenes super-infection. Vaccine. 32:5241-9, 2014.
Weeks-Gorospe JN, Hurtig HR, Iverson AR, Schuneman MJ, Webby RJ, McCullers JA, Huber VC. Naturally occurring swine influenza A virus PB1-F2 phenotypes that contribute to super-infection with Gram-positive respiratory pathogens. J Virol 85:9035-43, 2012.
Chaussee MS, Sandbulte HR, Schuneman MJ, DePaula FP, Addengast LA, Schlenker EH, and Huber VC. Inactivated and live, attenuated influenza vaccines protect mice against influenza:Streptococcus pyogenes super-infections. Vaccine 29:3773-81, 2011.
Huber VC, Peltola V, Iverson AR, and McCullers JA. Contribution of vaccine-induced immunity toward either the HA or the NA component of influenza viruses limits secondary bacterial complications. J Virol 84:4105-4108, 2010.
Huber VC, Thomas PG, and McCullers JA. A multi-valent approach that elicits broad immunity within an influenza subtype. Vaccine 27:1192-1200, 2009.
Huber VC, Kleimeyer LH, and McCullers JA. Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus. Vaccine 26:5381-5388, 2008.
Huber VC, McKeon RM, Brackin MN, Miller LA, Keating R, Brown SA, Makarova N, Perez DP, MacDonald GH, McCullers JA. Distinct contributions of vaccine-induced immunoglobulin G1 (IgG1) and IgG2a antibodies to protective immunity against influenza. Clin Vaccine Immunol 13:981-990, 2006.
Huber VC, McCullers JA. Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets. J Infect Dis 193:677-684, 2006.
Huber VC, Lynch JM, Bucher DJ, Le J, Metzger DW. FcR-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166:7381-7388, 2001.
Return to Members main page.